Novacyt (ALTERNEXT: ALNOV), an international specialist in cancer and infectious disease diagnostics, reported earlier its strong first-half sales performance across the Group and the completion of €3.5m in bond refinancing....
Novacyt (ALTERNEXT: ALNOV), an international specialist in cancer and infectious disease diagnostics is pleased to announce the addition of new members to its Board as the Company prepares for the next...
Novacyt (ALTERNEXT: ALNOV), an international specialist in cancer and infectious disease diagnostics, today announces its audited financial statement for the year ending 31st December, 2014, approved by the Board of...
Novacyt (ALTERNEXT: ALNOV), an international specialist in cancer and infectious disease diagnostics, today announces a private equity placement financing of €2.2m. This new financing will be used to accelerate the...
Novacyt (ALTERNEXT: ALNOV), an international specialist in cancer and infectious disease diagnostics, has appointed Manuela Gazzard as Commercial Director. Download press release...
Novacyt (ISIN Code: FR0010397232 - Mnemonic code: ALNOV), an international specialist in cancer and infectious disease diagnostics, today announces its unaudited revenues for 2014. Download press release...
Novacyt (ISIN Code: FR0010397232 - Mnemonic code: ALNOV), an international specialist in cancer and infectious disease diagnostics, today announces that Oriel Securities, a stock market research firm, based in London, has initiated...
Novacyt (ISIN Code: FR0010397232 - Mnemonic code: ALNOV), an international specialist in cancer and infectious disease diagnostics, today announces that its stock will transition to continuous trading starting 15th of...
Novacyt (ALTERNEXT: ALNOV), an international specialist in cancer and infectious disease diagnostics, today announces a private equity placement financing of €3.1m. Download press release...
Novacyt (ALTERNEXT: ALNOV), an international specialist in cancer and infectious disease diagnostics, today announces its half year results for the six months ended 30th June 2014 approved by the Board...
| Cookie | Duration | Description |
|---|---|---|
| cookielawinfo-checkbox-analytics | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics". |
| cookielawinfo-checkbox-functional | 11 months | The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional". |
| cookielawinfo-checkbox-necessary | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary". |
| cookielawinfo-checkbox-others | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other. |
| cookielawinfo-checkbox-performance | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance". |
| viewed_cookie_policy | 11 months | The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data. |
